**ICD-O-3.2 Update**

**Effective January 1, 2022**

**Table 1: 2022 ICD-O-3.2 Update (Numerical)**

* Codes/terms listed numerically
* **Only new** associated terminology to **existing ICD-O-3.2** codes are included in the 2022 ICD-O Implementation guidelines and documentation. Terms are those listed in the blue books.
* Update based on the following 5th Ed classification of Tumors books: Breast, Digestive System, Female Genital, and Soft Tissue & Bone

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **ICD-O Code** | **Term** | **Required****SEER** | **Required****NPCR** | **Required****CoC** | **Required****CCCR** | **Remarks** |
| 8033/3 | Carcinoma with sarcomatoid component  | Y | Y | Y | Y | New related term  |
| 8044/3 | Small cell carcinoma, large cell variant **(C56.9)** | Y | Y | Y | Y | New related term: ***ovary only*** |
| 8085/3 | Squamous cell carcinoma, HPV-associated | Y | Y | Y | Y | New term for uterine cervix, vagina, vulva valid 1/1/2022 |
| 8086/3 | Squamous cell carcinoma, HPV-independent | Y | Y | Y | Y | New term for uterine cervix, vagina, vulva valid 1/1/2022 |
| 8144/2 | Intestinal-type adenoma, high grade **(C160 – C166, C168-C169, C170-C173, C178-C179)** | Y**See remarks** | Y**See remarks** | Y**See remarks** | Y**See Remarks\*** | Term is reportable for stomach and small intestines **ONLY beginning 1/1/2022****\*CCCR required High Grade Dysplasia 2010+ for all GI sites; stopped for C18.\_, C19.\_, and C20.\_ in 2018** |
| 8150/3 | Oncocytic neuroendocrine tumor, non-functioning pancreatic | Y | Y | Y | Y | New related term |
| 8150/3 | Pleomorphic neuroendocrine tumor, non-functioning pancreatic | Y | Y | Y | Y | New related term |
| 8150/3 | Clear cell neuroendocrine tumor, non-functioning pancreatic | Y | Y | Y | Y | New related term |
| 8150/3 | Cystic neuroendocrine tumor, non-functioning pancreatic  | Y | Y | Y | Y | New related term |
| 8174/3 | Hepatocellular carcinoma, steatohepatitic | Y | Y | Y | Y | New related term |
| 8174/3 | Hepatocellular carcinoma, macrotrabecular massive | Y | Y | Y | Y | New related term |
| 8174/3 | Hepatocellular carcinoma, chromophobe | Y | Y | Y | Y | New related term |
| 8174/3 | Hepatocellular carcinoma, neutrophil-rich | Y | Y | Y | Y | New related term |
| 8174/3 | Hepatocellular carcinoma, lymphocyte-rich | Y | Y | Y | Y | New related term |
| 8200/3 | Solid-basaloid adenoid cystic carcinoma | Y | Y | Y | Y | New related term |
| 8200/3 | Adenoid cystic carcinoma with high-grade transformation | Y | Y | Y | Y | New related term |
| 8210/2 | Adenomatous polyp, high grade dysplasia **(C160 – C166, C168-C169, C170-C173, C178-C179)** | Y**See remarks** | Y**See remarks** | N | Y**See Remarks\*** | Term is reportable for stomach and small intestines **ONLY beginning 1/1/2022****\*CCCR required High Grade Dysplasia 2010+ for all GI sites; stopped for C18.\_, C19.\_, and C20.\_ in 2018** |
| 8211/2 | Tubular adenoma, high grade | N | N | N | Y**See Remarks\*** | Term is NOT reportable**\*CCCR required High Grade Dysplasia 2010+ for all GI sites; stopped for C18.\_, C19.\_, and C20.\_ in 2018** |
| 8213/2 | Serrated dysplasia, high grade **(C160 – C166, C168-C169, C170-C173, C178-C179)** | Y**See remarks** | Y**See remarks** | Y**See remarks** | Y**See Remarks\*** | Term is reportable for stomach and small intestines **ONLY beginning 1/1/2022****\*CCCR required High Grade Dysplasia 2010+ for all GI sites; stopped for C18.\_, C19.\_, and C20.\_ in 2018** |
| 8243/3 | **Goblet cell adenocarcinoma** | Y | Y | Y | Y | New preferred term |
| 8261/2 | Villous adenoma, high grade | N | N | N | Y**See Remarks\*** | Term is NOT reportable **\*CCCR required High Grade Dysplasia 2010+ for all GI sites; stopped for C18.\_, C19.\_, and C20.\_ in 2018** |
| 8262/3 | Adenoma-like adenocarcinoma | Y | Y | Y | Y | New related term |
| 8263/2 | Tubulovillous adenoma, high grade | N | N | N | Y**See Remarks\*** | Term is NOT reportable**\*CCCR required High Grade Dysplasia 2010+ for all GI sites; stopped for C18.\_, C19.\_, and C20.\_ in 2018** |
| 8310/3 | Adenocarcinoma, HPV-independent, clear cell type | Y | Y | Y | Y | New term for uterine cervix |
| 8455/2 | **Intraductal oncocytic papillary neoplasm, NOS** **(C250-C254, C257-C259)** | Y | Y | Y | Y | New ICD-O code/term |
| 8455/3 | **Intraductal oncocytic papillary neoplasm with associated invasive carcinoma(C250-C254, C257-C259)** | Y | Y | Y | Y | New ICD-O code/term |
| 8480/2 | Low grade appendiceal mucinous neoplasm (LAMN) **(C181)** | Y | Y | Y | Y | ICD-O-3.2 currently lists LAMN as 8480/1. Beginning with cases diagnosed 1/1/2022 forward, LAMN should be assigned a behavior code of /2. LAMN diagnosed prior to 1/1/2022 is not reportable. |
| 8480/2 | High grade appendiceal mucinous neoplasm (HAMN) **(C181)** | Y | Y | Y | Y | New behavior/term |
| 8482/3 | Adenocarcinoma, HPV-independent, gastric type (**C530-C531, C538-C539)** | Y | Y | Y | Y | New related term |
| 8483/2 | **Adenocarcinoma in situ, HPV-associated** (**C530-C531, C538-C539)** | N | N | N | N | New ICD-O code/termNot reportable |
| 8483/3 | **Adenocarcinoma, HPV-associated** **C530-C531, C538-C539)** | Y | Y | Y | Y | New ICD-O code/term |
| 8484/2 | **Adenocarcinoma in situ, HPV-independent, NOS** **C530-C531, C538-C539)** | N | N | N | N | New ICD-O code/termNot reportable |
| 8484/3 | **Adenocarcinoma, HPV-independent, NOS** **C530-C531, C538-C539)** | Y | Y | Y | Y | New ICD-O code/term |
| 8500/2 | DCIS of low nuclear grade | Y | Y | Y | Y | New related term |
| 8500/2 | DCIS of intermediate nuclear grade | Y | Y | Y | Y | New related term |
| 8500/2 | DCIS of high nuclear grade | Y | Y | Y | Y | New related term |
| 8503/2 | **Ductal carcinoma in situ, papillary** | Y | Y | Y | Y | New preferred term |
| 8509/3 | **Tall cell carcinoma with reversed polarity** | Y | Y | Y | Y | New preferred term |
| 8520/2 | Florid lobular carcinoma in situ | Y | Y | Y | Y | New related term |
| 8576/3 | Paneth cell carcinoma  | Y | Y | Y | Y | New related term |
| 8590/1  | Uterine tumor resembling ovarian sex cord tumor | N | N | N | N | Existing code with new behavior-not Reportable |
| 8804/3 | Proximal or large cell epithelioid sarcoma | Y | Y | Y | Y | New related term |
| 8804/3 | Classic epithelioid sarcoma | Y | Y | Y | Y | New related term |
| 8811/3 | Epithelioid myxofibrosarcoma | Y | Y | Y | Y | New related term |
| 8832/3 | Myxoid dermatofibrosarcoma protuberans | Y | Y | Y | Y | New related term |
| 8832/3 | Dermatofibrosarcoma protuberans with myoid differentiation  | Y | Y | Y | Y | New related term |
| 8832/3 | Plaque-like dermatofibrosarcoma protuberans  | Y | Y | Y | Y | New related term  |
| 8859/3 | **Myxoid pleomorphic liposarcoma** | Y | Y | Y | Y | New ICD-O code/term |
| 8912/3 | Congenital spindle cell rhabdomyosarcoma with VGLL2/NCOA2/CITED2 rearrangements | Y | Y | Y | Y | New related term |
| 8912/3 | MYOD1-mutant spindle cell/sclerosing rhabdomyosarcoma | Y | Y | Y | Y | New related term |
| 8912/3 | Intraosseous spindle cell rhabdomyosarcoma with TFCP2/NCOA2 rearrangements | Y | Y | Y | Y | New related term |
| 8976/3 | **Gastroblastoma (C16.0 – C16.9)** | Y | Y | Y | Y | New ICD-O code/term |
| 8990/3 | NTRK-rearranged spindle cell neoplasm (emerging) | Y | Y | Y | Y | New related term |
| 9110/3 | **Adenocarcinoma, HPV-independent, mesonephric type** | Y | Y | Y | Y | New preferred term |
| 9111/3 | **Mesonephric-like adenocarcinoma** | Y | Y | Y | Y | New ICD-O code/term for ovary and corpus uterus |
| 9120/3 | Post radiation angiosarcoma of the breast  | Y | Y | Y | Y | New related term |
| 9120/3 | Epithelioid angiosarcoma | Y | Y | Y | Y | New related term |
| 9133/3 | Epithelioid hemangioendothelioma with WWTR1-CAMTA1 fusion | Y | Y | Y | Y | New related term |
| 9133/3 | Epithelioid hemangioendothelioma with YAP1-TFE3 fusion | Y | Y | Y | Y | New related term |
| 9140/3 | Classic indolent Kaposi sarcoma | Y | Y | Y | Y | New related term |
| 9140/3 | Endemic African Kaposi sarcoma | Y | Y | Y | Y | New related term |
| 9140/3 | AIDS-associated Kaposi sarcoma | Y | Y | Y | Y | New related term |
| 9140/3 | Iatrogenic Kaposi sarcoma | Y | Y | Y | Y | New related term |
| 9200/1 | Osteoblastoma | N | N | N | N | Behavior change from /0 to /1. Remains **non-reportable** |
| 9222/3 | Chondrosarcoma, grade 1 | Y | Y | Y | Y | Behavior change. **Reportable 1/1/2022 forward** |
| 9261/1 | Osteofibrous dysplasia-like adamantinoma | N | N | N | N | New behavior code/term. **Non-reportable** |
| 9366/3 | Round cell sarcoma with EWSR1-non-ETS fusions | Y | Y | Y | Y | New ICD-O code/term |
| 9367/3 | CIC-rearranged sarcoma | Y | Y | Y | Y | New ICD-O code/term |
| 9368/3 | Sarcoma with BCOR genetic alterations | Y | Y | Y | Y | New ICD-O code/term |
| 9687/3 | Endemic Burkitt lymphoma | Y | Y | Y | Y | New related term |
| 9687/3 | Sporadic Burkitt lymphoma | Y | Y | Y | Y | New related term |
| 9687/3 | Immunodeficiency-associated Burkitt lymphoma | Y | Y | Y | Y | New related term |
| 9718/1 | Primary cutaneous CD30 positive T-cell lympho-proliferation disorder | N | N | N | N | No longer reportable as/3 for cases diagnosed after 1/1/2010. See the Hematopoietic & Lymphoid Database for information |